MS/AL Radiation Oncology Research Partnership

MS/AL 放射肿瘤学研究合作伙伴关系

• 批准号: 7487821
• 负责人: James E. Clarkson
• 金额: $ 29.19万
• 依托单位: SINGING RIVER HEALTH SYSTEM
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-26 至 2010-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7487821
• 关键词: Appendix; Child; Clinical Trials; Data; Development Plans; Face; Instruction; Letters; Literature; Manuscripts; Methods; Monitor; None or Not Applicable; Numbers; Phase; Progress Reports; Publications; Radiation Oncology; Reporting; Research; Research Design; Resources; Safety; Vertebrates; Woman; human subject

........... 26-42 Other Biographical Sketches (Not to exceed four pages for each - See instructions)) ........................ 43-46 Resources ................................................................................................................................................. Research Plan 47-68 Introduction to Revised Application (Not to exceed 3 pages) ......................................................................................................... NtA_ Introduction to Supplemental Application (Not to exceed one page) .............................................................................................. N/A N/A A. Specific Aims ......................................................................... _. .................................................................................... _ 47 B. Background and Significance ................................................... _.................................................................................... I'" N/A__ C. Preliminary Studies/Progress Report/ _. (Items A-D: not to exceed 25 pages*) .._ Phase 1Progress Report (SBIP-JSTTR Phase II ONLY) _ * SBIRJSTTR Phase h Items A-D fimited to 15 pages. D, Research Design and Methods ............................................. _ | ..................................................................................... I N/A_ E. Human Subjects ................................................................................................................................................................. 64-65 Protection of Human Subjects (Required if Item 4 on the Face Page is marked "yes") __ 64 Inclusion of Women (Required if Item 4 on the Face Page is marked "Yes") ................................................................. ___ 65_. Inclusion of Minodties (Required if Item 4 on the Face Page is marked "Yes") ............................................................... 65 Inclusion of Children (Required if Item 4 on the Face Page is marked "Yes") ................................................................. 65 Data and Safety Monitoring Plan (Required if Item 4 on the Face Page is marked '_es" anda Phase 1, II, or III clinical trial is proposed ...................................................................................................................................................... N/A F. Vertebrate Animals ............................................................................................................................................................. __ N/A_ G, Literature Cited ................................................................................................................................................................... ..... 69 H. Consortium/Contractual Arrangements ............................................................................................................................... 70 I. Letters of Support (e,g., Consultants) ................................................................................................................................. j1 -EA__ J. Product Development Plan (SBIP-JSTTR Phase II and Fast-Track ONLY) .......................................................................... N/A Checklist .................................................................................................................................................... 75 Check if Appendix (Five collated sets. No page numbering necessary for Appendix.) Appendix is Included Appendices NOT PERM/TTED for Phase / SB/R/S TTR unless specifically solicited, Number of publications and manuscripts accepted for publication (not to exceed 10) Other items (list): PHS 398 (Rev. 05101) Page 3 Form Page 3

........... 26-42 其他个人简介（每份不超过四页-见说明）........................ 43-46 资源.... 研究计划 47-68 修订申请简介（不超过3页）.... NtA_ 补充申请简介（不超过一页）....... N/A N/A A.具体目标....... _. .................................................................................... 第四十七章 B。背景及意义......................................................................... _....................................................................................我“ 不适用__ C.初步研究/进度报告/ _。（项目A-D：不超过25页 *）._ 第1阶段进度报告（仅限SBIP-JSTTR第II阶段）_ * SBIRJSTTR第h阶段项目A-D限定为15页。 D，研究设计和方法.............................................. _ | .....................................................................................不适用_ E.人类受试者................................................................................................................................................................. 64-65 人类受试者保护（如果正面页上的第4项标记为“是”，则需要）__ 64 纳入女性（如果正面页面上的项目4标记为“是”，则需要）... _ 65_. 包括次要内容（如果正面页面上的第4项标记为“是”，则需要）.... 65 纳入儿童（如果正面页上的第4项标记为“是”，则需要）..... 65 数据和安全性监测计划（如果正面页上的项目4标记为“_es”，则需要1期、II期或III期临床试验） 建议试用...................................................................................................................................................... N/A F.脊椎动物.............................................................................................................................................................不适用 G、引用的文献................................................................................................................................................................... ..... 69 H.联合体/合同安排...... 70 I.支持信（例如，顾问）... j1 -EA__ J.产品开发计划（仅限SBIP-JSTTR第二阶段和快速通道）... N/A 核对表.. 75 检查是否 附录（五个整理集。附录无需页码。） 阑尾是 包括 除非特别要求，否则附录不适用于阶段/ SB/R/S TTR， 接受出版的出版物和手稿数量（不超过10份） 其他项目（列表）： PHS 398（版本05101）第3页表格第3页